CL2017000002A1 - Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3 tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer - Google Patents

Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3 tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer

Info

Publication number
CL2017000002A1
CL2017000002A1 CL2017000002A CL2017000002A CL2017000002A1 CL 2017000002 A1 CL2017000002 A1 CL 2017000002A1 CL 2017000002 A CL2017000002 A CL 2017000002A CL 2017000002 A CL2017000002 A CL 2017000002A CL 2017000002 A1 CL2017000002 A1 CL 2017000002A1
Authority
CL
Chile
Prior art keywords
indol
fluoro
treatment
tetrafluoropropoxy
alzheimer
Prior art date
Application number
CL2017000002A
Other languages
English (en)
Spanish (es)
Inventor
Kristine Birklund Andersen
Michael Harold Rock
Diego Heidi Lopez De
Frans Dennis Therkelsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58794010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017000002(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of CL2017000002A1 publication Critical patent/CL2017000002A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2017000002A 2014-07-04 2017-01-03 Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3 tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer CL2017000002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400369 2014-07-04

Publications (1)

Publication Number Publication Date
CL2017000002A1 true CL2017000002A1 (es) 2017-06-23

Family

ID=58794010

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000002A CL2017000002A1 (es) 2014-07-04 2017-01-03 Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3 tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer

Country Status (42)

Country Link
US (1) US10071963B2 (ar)
EP (1) EP3164385B1 (ar)
JP (2) JP6643330B2 (ar)
KR (1) KR102399374B1 (ar)
CN (3) CN112961094A (ar)
AP (1) AP2016009643A0 (ar)
AR (1) AR101109A1 (ar)
AU (1) AU2015282909B2 (ar)
CA (1) CA2951794C (ar)
CL (1) CL2017000002A1 (ar)
CO (1) CO2017000019A2 (ar)
CR (1) CR20160605A (ar)
CY (1) CY1124594T1 (ar)
DK (1) DK3164385T3 (ar)
DO (1) DOP2017000001A (ar)
EA (1) EA035894B1 (ar)
EC (1) ECSP17000222A (ar)
ES (1) ES2893619T3 (ar)
GE (2) GEP20227368B (ar)
HR (1) HRP20211596T8 (ar)
HU (1) HUE056368T2 (ar)
IL (1) IL249428B (ar)
JO (1) JO3639B1 (ar)
LT (1) LT3164385T (ar)
MA (1) MA40345B1 (ar)
MX (1) MX377013B (ar)
MY (1) MY190715A (ar)
NZ (1) NZ727251A (ar)
PE (1) PE20170522A1 (ar)
PH (1) PH12016502477A1 (ar)
PL (1) PL3164385T3 (ar)
PT (1) PT3164385T (ar)
RS (1) RS62380B1 (ar)
RU (1) RU2016151637A (ar)
SG (1) SG11201610334XA (ar)
SI (1) SI3164385T1 (ar)
SM (1) SMT202100575T1 (ar)
SV (1) SV2016005353A (ar)
TN (1) TN2016000549A1 (ar)
TW (1) TWI665188B (ar)
UA (1) UA121547C2 (ar)
WO (1) WO2016001398A1 (ar)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333154A1 (en) 2016-12-07 2018-06-13 Sandoz Ag Crystalline form of a selective 5-ht6 receptor antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566056T3 (es) 2001-03-29 2016-04-08 Eli Lilly And Company N-(2-ariletil)bencilaminas como antagonistas del receptor 5-HT6
TW201139370A (en) * 2009-12-23 2011-11-16 Lundbeck & Co As H Processes for the manufacture of a pharmaceutically active agent
JO3459B1 (ar) * 2012-09-09 2020-07-05 H Lundbeck As تركيبات صيدلانية لعلاج مرض الزهايمر
CN105175307A (zh) 2014-11-18 2015-12-23 苏州晶云药物科技有限公司 Lu AE58054的盐酸盐晶型A及其制备方法和用途

Also Published As

Publication number Publication date
HRP20211596T8 (hr) 2022-03-04
AU2015282909B2 (en) 2019-02-07
KR102399374B1 (ko) 2022-05-17
JP6643330B2 (ja) 2020-02-12
WO2016001398A1 (en) 2016-01-07
SG11201610334XA (en) 2017-01-27
CY1124594T1 (el) 2022-07-22
TN2016000549A1 (en) 2018-04-04
PE20170522A1 (es) 2017-05-28
CO2017000019A2 (es) 2017-05-31
SV2016005353A (es) 2017-03-23
HRP20211596T1 (hr) 2022-01-07
MX377013B (es) 2025-03-07
RU2016151637A3 (ar) 2019-01-28
JP2020059724A (ja) 2020-04-16
PH12016502477B1 (en) 2017-04-10
LT3164385T (lt) 2021-10-11
PL3164385T3 (pl) 2021-12-20
US10071963B2 (en) 2018-09-11
DOP2017000001A (es) 2017-03-31
CR20160605A (es) 2017-04-24
UA121547C2 (uk) 2020-06-25
BR112017000127A2 (pt) 2018-01-23
JP2017519829A (ja) 2017-07-20
KR20170023019A (ko) 2017-03-02
MA40345A (fr) 2021-04-28
CN112961094A (zh) 2021-06-15
EP3164385A1 (en) 2017-05-10
PT3164385T (pt) 2021-10-07
AP2016009643A0 (en) 2016-12-31
NZ727251A (en) 2023-06-30
SI3164385T1 (sl) 2021-10-29
CA2951794C (en) 2023-03-07
EP3164385B1 (en) 2021-09-08
MY190715A (en) 2022-05-12
CA2951794A1 (en) 2016-01-07
CN112961095A (zh) 2021-06-15
IL249428B (en) 2019-10-31
EA035894B1 (ru) 2020-08-27
ECSP17000222A (es) 2017-02-24
DK3164385T3 (da) 2021-10-11
TW201625525A (zh) 2016-07-16
GEAP202114363A (en) 2021-12-10
RU2016151637A (ru) 2018-08-08
SMT202100575T1 (it) 2021-11-12
EA201692485A1 (ru) 2017-05-31
AU2015282909A1 (en) 2017-01-05
MX2016016895A (es) 2017-04-27
JO3639B1 (ar) 2020-08-27
PH12016502477A1 (en) 2017-04-10
CN106458889A (zh) 2017-02-22
MA40345B1 (fr) 2021-10-29
US20170152227A1 (en) 2017-06-01
IL249428A0 (en) 2017-02-28
TWI665188B (zh) 2019-07-11
HUE056368T2 (hu) 2022-02-28
GEP20227368B (en) 2022-03-25
ES2893619T3 (es) 2022-02-09
AR101109A1 (es) 2016-11-23
RS62380B1 (sr) 2021-10-29

Similar Documents

Publication Publication Date Title
MX2017002670A (es) Inhibidores de glucosidasa.
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
DK3463351T3 (da) Behandling til parkinsons sygdom
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
PH12017501955A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer`s disease
CO2017000019A2 (es) Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer
PE20181019A1 (es) Monohidrato de (s)-lactato de 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino)pirazin-2-carbonitrilo
LT3148588T (lt) N,n-bis-2-merkaptoetilizoftalamidas, skirtas parkinsono ligos gydymui
TH1601002537A (th) กระบวนการสำหรับการสังเคราะห์สารยับยั้งอินโดลเอมีน 2,3-ไดออกซีจีเนสชนิดหนึ่ง
EA201691620A1 (ru) Циклопропиламины в качестве ингибиторов lsd1